Author:
Zhen Liang,Juan Wang,Tianrui Feng,Yuliang Chen,Zhien Zhou,Yi Zhou,Weigang Yan,Fenghong Cao
Funder
Chinese Academy of Medical Sciences & Peking Union Medical College
Reference60 articles.
1. Ra-223 induces clustered DNA damage and inhibits cell survival in several prostate cancer cell lines;Abramenkovs;Transl. Oncol.,2022
2. Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure;Alyamani;Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.,2020
3. Population, intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews;Amir-Behghadami;Emerg. Med. J.,2020
4. Arches: a randomized, phase III study of androgen deprivation therapy with enzalutamide or Placebo in men with metastatic hormone-sensitive prostate cancer;Armstrong;J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.,2019
5. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven;Attard;J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.,2008
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献